Cyanine 5 EGFP mRNA is designed for the analysis of mRNA delivery and translation efficiency. The EGFP mRNA will express an enhanced version of the green fluorescent protein, originally isolated from the jellyfish, Aequorea victoria. EGFP is a commonly used direct detection reporter in mammalian cell culture, yielding bright green fluorescence with an emission peak at 509 nm. When labeled with cyanine 5, EGFP mRNA can be directly visualized. Cyanine 5 EGFP mRNA is an ideal molecule to determine mRNA delivery and localization independent of translation.
Cyanine 5 is a synthetic fluorescent dye with maximum excitation and emission wavelengths of 650 nm and 670 nm respectively. TriLink’s CleanCap Cyanine 5 EGFP mRNA is transcribed with Cyanine 5-UTP:5-Methoxy-UTP at a ratio of 1:3. Substitution in this ratio results in mRNA that is easily visualized and can still be translated in cell culture. Translation efficiency correlates inversely with Cyanine 5-UTP substitution.
This mRNA is capped using CleanCap, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, modified with 5-methoxyuridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.
|Purity||Passes Agarose Gel Mobility|
|Base Composition||Fully substituted with 5-Methoxy-U|
|Buffer||1 mM Sodium Citrate pH 6.4|
|Conversion Factor||40 µg/OD260|
|Recommended Storage||At or below -40°C|
|Other Name(s)||CleanCap®Cyanine 5 Enhanced Green Fluorescent Protein mRNA (5-methoxyuridine)|
CleanCap For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at trilinkbiotech.com/cleancap-research-license.
Mutant GFP mRNA These products are sold with a Limited Use Label License under sublicense with Life Technologies, Inc. Please review Limited License at trilinkbiotech.com/gfp-label-license.
Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission of Seller. No license under any patent or other intellectual property right of Seller or its licensors is granted or implied by the purchase unless otherwise provided in writing.
TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.
Verbeke, Rein; Lentacker, Ine; Wayteck, Laura; Breckpot, Karine; Van Bockstal, Mieke; Descamps, Benedicte; Vanhove, Christian; De Smedt, Stefaan C.; Dewitte, Heleen . Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA.